Mattke, Matthias http://orcid.org/0000-0001-5057-6065
Ohlinger, Matteo
Bougatf, Nina
Harrabi, Semi
Wolf, Robert
Seidensaal, Katharina
Welzel, Thomas
Röder, Falk
Gerum, Sabine
Ellerbrock, Malte
Jäkel, Oliver
Haberer, Thomas
Herfarth, Klaus
Uhl, Matthias
Debus, Jürgen
Funding for this research was provided by:
Paracelsus Medical University
Article History
Received: 22 February 2022
Accepted: 30 August 2022
First Online: 23 September 2022
Declarations
:
: M. Mattke received travel grants from Pharmamar. F. Röder received speaker honoraria and travel grants from Intraop Medical, Lilly Germany, and Pharmamar. J. Debus is head of the Department of Radiation Oncology in Heidelberg and the CEO of the Heidelberg Ion-Beam Therapy Center; he declares to receiving grants from Viewray Inc., CRI The Clinical Research Institute GmbH, Accuray International Sari, RaySearch Laboratories AB, Vision RT Limited, Merck Serono GmbH, Astellas Pharma GmbH, Astra Zeneca GmbH, Siemens Healthcare GmbH, Solution Akademie GmbH, Egomed PLC Surrey Research Park, Quintiles GmbH, Pharmaceutical Research Associates GmbH, Boehringer Ingelheim Pharma GmbH&CoKG, PTW-Freiburg Dr. Pychlau GmbH, Nanobiotix SA, and Accuray Incorporated. M. Ohlinger, N. Bougatf, S. Harrabi, R. Wolf, K. Seidensaal, T. Welzel, S. Gerum, M. Ellerbrock, O. Jäkel, T. Haberer, K. Herfarth, and M. Uhl declare that they have no competing interests.
: The study was approved by the ethics committee of the University of Heidelberg.